Alnylam Pharmace. buy Subdi
Summary
This prediction ended on 06.09.18 with a price of €105.44. With a performance of -4.71%, the BUY prediction by Subdi finished with a loss. Subdi has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | 3.105% | 3.105% | -49.540% | 15.421% |
| iShares Core DAX® | -0,87 % | 5,32 % | 6,86 % | 65,21 % |
| iShares Nasdaq 100 | -0,38 % | 1,98 % | 25,70 % | 90,33 % |
| iShares Nikkei 225® | -1,68 % | 1,95 % | 41,44 % | 80,62 % |
| iShares S&P 500 | -0,65 % | 2,07 % | 21,40 % | 70,74 % |
Comments by Subdi for this prediction
In the thread Alnylam Pharmace. diskutieren
Subdi stimmt der Buy-Einschätzung von stratec zu
Subdi stimmt am 31.08.2018 der Buy-Einschätzung von stratec mit dem Kursziel 146,78$ zu.
Überschrift: Alnylam with its first new drug application and multiple clinical read-outs in 2018
Stopped prediction by Subdi for Alnylam Pharmace.
Alnylam Pharmace.
27.10.18
08.11.18
08.11.18
Alnylam Pharmace.
10.09.18
12.09.18
12.09.18